Arbutus Biopharma (ABUS) Misses Q2 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. WCN
7. SPOT
8. SPY
9. FIX
10. TSCO

Go back to Arbutus Biopharma (ABUS) Misses Q2 EPS by 1c

Arbutus Reports Second Quarter 2021 Financial Results and Provides Corporate Update

August 5, 2021 7:30 AM EDT

New data on AB-729, Arbutus proprietary subcutaneously delivered RNAi agent, highlighted in four abstracts at the EASL International Liver Congress; all AB-729 abstracts selected for best of ILC

Announced two additional proof-of-concept clinical collaborations to evaluate AB-729 in combination with agents from Vaccitech plc and Antios Therapeutics, Inc.

Announced U.S. Food and Drug Administration (FDA) authorization to proceed with an Investigational New Drug (IND) application in a Phase 2a clinical trial to investigate the safety and anti-viral activity of... More